Treatment for Cannabis Use

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Connecticut Mental Health Center, New Haven, CT
Cannabis Use+1 More
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The aim of the study is to examine the effect of cannabis use on brain synaptic density among older adults using [11C]UCB-J PET imaging.

Eligible Conditions

  • Cannabis Use

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Cannabis Use

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 1 month

1 month
Hippocampal synaptic density

Trial Safety

Safety Progress

1 of 3

Other trials for Cannabis Use

Trial Design

0 Treatment Group

24 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · Phase 1 & 2

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 month
Closest Location: Connecticut Mental Health Center · New Haven, CT
Photo of New Haven 1Photo of New Haven 2Photo of New Haven 3
2013First Recorded Clinical Trial
1 TrialsResearching Cannabis Use
41 CompletedClinical Trials

Who is running the clinical trial?

National Institute on Drug Abuse (NIDA)NIH
2,203 Previous Clinical Trials
5,610,455 Total Patients Enrolled
20 Trials studying Cannabis Use
1,948 Patients Enrolled for Cannabis Use
Yale UniversityLead Sponsor
1,653 Previous Clinical Trials
20,829,940 Total Patients Enrolled
2 Trials studying Cannabis Use
30 Patients Enrolled for Cannabis Use
Rajiv Radhakrishnan, MBBS, MDPrincipal InvestigatorYale University

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.